跳至主要内容
临床试验/NCT06406387
NCT06406387进行中(未招募)不适用

Association Between Endoscopic Ultrasound Based Preoperative ATRX/DAXX Immunohistochemistry Expression and Prognosis of Sporadic, Non-FunctiOnal pancREatic Neuroendocrine tumorS: a prospEctivE Cohort Study

Azienda Ospedaliera Universitaria Integrata Verona1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2024年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
100
试验地点
1
主要终点
ATRX/DAXX loss-tumor aggressiveness association

研究概览

简要总结

P-NENs are classified as functional (F-) or non-functional (NF-) depending on the presence or absence of a clinical hormonal hypersecretion syndrome. Moreover, the WHO 2017 classification of pNENs distinguishes between well-differentiated pancreatic neuroendocrine tumors (pNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (pNECs). pNETs are then divided according to a grading scheme based on Ki67 index in pNETs-G1 (Ki67 index ≤3%) and pNETs-G2 (Ki67 index between 4% and 20%). pNECs are all G3, with a Ki67 index >20%. Endoscopic ultrasound with fine-needle biopsy (EUS-FNB) demonstrated safe and effective preoperative grading based on the Ki-67 proliferative index. However, downstaging rate is not neglectable, reaching 15% in a recent metanalysis. Moreover, recent whole-exome and whole genome sequencing studies revealed that the mutually exclusive inactivating mutations in death domain-associated protein (DAXX) and/or in α-thalassemia/mental retardation X-linked (ATRX) chromatin remodeling genes are associated with more aggressive disease. In a retrospective study, the investigators recently evaluated the correspondence of DAXX/ATRX expression on 41 EUS-FNB samples with corresponding surgical specimens demonstrating a 95.1% (almost perfect agreement, κ = 0.828; p < 0.001) and 92.7% (substantial agreement, κ = 0.626; p < 0.001) concordance for DAXX and ATRX expression, respectively. This study aims to evaluate the potential clinical/prognostic role of DAXX/ATRX expression as implementation of the currently used Ki67-based grading, evaluated on EUS-FNB samples in a prospective cohort of patients with NF-pNETs

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥18 years
  • Cyto/histologic diagnosis of pNETs
  • Signed informed consent

排除标准

  • Functional pNETs
  • Multiple pancreatic nodules
  • Diagnosis of MEN-1 or Von-Hippel Lindau
  • Mixed types (e.g., mixed neuroendocrine-acinar/adenocarcinoma) or neuroendocrine carcinomas
  • Predominantly cystic lesions (more than 50% of the volume).
  • Metastatic tumors at the time of diagnosis
  • Known bleeding disorder that cannot be sufficiently corrected with co-fact or fresh frozen plasma
  • Use of anticoagulants that cannot be discontinued
  • INR >1.5 or platelet count <50.000
  • Pregnancy or breastfeeding
  • Failure to sign the patient's or closest relative's informed consent

结局指标

主要结局

ATRX/DAXX loss-tumor aggressiveness association

时间窗: 18 months

To assess the association between ATRX/DAXX loss of expression assessed on endoscopic ultrasound biopsy specimens and pathological features indicative of tumor aggressiveness evaluated on surgical pathology

次要结局

  • DAXX/ATRX concordance(18 months)
  • Preoperative prognosis assessment(60 months)
  • Ki-67 concordance(18 months)
  • Ki-67-tumor aggressiveness association(18 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验